See the DrugPatentWatch profile for tigecycline
Global Variations in Tigecycline Resistance among Anaerobes: A Continental Perspective
Anaerobic bacteria, which thrive in environments devoid of oxygen, pose a significant threat to human health worldwide. These microorganisms are responsible for a range of infections, from skin and soft tissue infections to life-threatening conditions such as sepsis and meningitis. Tigecycline, a broad-spectrum antibiotic, has been a valuable tool in the fight against anaerobic infections. However, the emergence of tigecycline resistance among anaerobes has become a pressing concern, with significant variations observed across different continents.
The Rise of Tigecycline Resistance
Tigecycline, a glycylcycline antibiotic, was approved by the US FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI), complicated intra-abdominal infections (cIAI), and community-acquired bacterial pneumonia (CABP). Its broad-spectrum activity against both Gram-positive and Gram-negative bacteria, including anaerobes, made it an attractive option for treating complex infections. However, as with any antibiotic, the overuse and misuse of tigecycline have contributed to the development of resistance.
Anaerobes: A Growing Concern
Anaerobes are a diverse group of bacteria that are capable of surviving in environments with low or no oxygen. They are commonly found in the human gut, skin, and respiratory tract, but can also be isolated from environmental sources such as soil and water. Anaerobes are responsible for a range of infections, including:
* Clostridioides difficile (C. diff): a bacterium that causes diarrhea and colitis, often associated with antibiotic use
* Bacteroides fragilis: a bacterium that can cause abdominal infections and sepsis
* Fusobacterium nucleatum: a bacterium that can cause periodontal disease and sepsis
Tigecycline Resistance among Anaerobes: A Continental Perspective
Studies have shown that tigecycline resistance among anaerobes varies significantly across different continents. For example:
* Asia: A study published in the Journal of Antimicrobial Chemotherapy found that tigecycline resistance among anaerobes in Asia was significantly higher than in other regions, with a reported resistance rate of 24.1% (1).
* Europe: A study published in the European Journal of Clinical Microbiology & Infectious Diseases found that tigecycline resistance among anaerobes in Europe was relatively low, with a reported resistance rate of 6.3% (2).
* North America: A study published in the Journal of Clinical Microbiology found that tigecycline resistance among anaerobes in North America was moderate, with a reported resistance rate of 12.5% (3).
Factors Contributing to Tigecycline Resistance
Several factors contribute to the development of tigecycline resistance among anaerobes, including:
* Overuse and misuse: The overuse and misuse of tigecycline have contributed to the development of resistance.
* Genetic mutations: Genetic mutations in the tigecycline target, the 30S ribosomal subunit, can confer resistance to the antibiotic.
* Horizontal gene transfer: The transfer of resistance genes between bacteria can spread resistance to other anaerobes.
Conclusion
Tigecycline resistance among anaerobes varies significantly across different continents, with Asia reporting the highest resistance rates. The overuse and misuse of tigecycline, genetic mutations, and horizontal gene transfer are contributing factors to the development of resistance. As the global burden of anaerobic infections continues to grow, it is essential to monitor tigecycline resistance and develop strategies to combat it.
Key Takeaways
* Tigecycline resistance among anaerobes varies significantly across different continents.
* Asia reports the highest tigecycline resistance rates among anaerobes.
* The overuse and misuse of tigecycline contribute to the development of resistance.
* Genetic mutations and horizontal gene transfer also play a role in the development of tigecycline resistance.
Frequently Asked Questions
1. What is tigecycline?
Tigecycline is a broad-spectrum antibiotic used to treat complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia.
2. What are anaerobes?
Anaerobes are a diverse group of bacteria that are capable of surviving in environments with low or no oxygen.
3. What are the common anaerobes that cause infections?
Common anaerobes that cause infections include Clostridioides difficile, Bacteroides fragilis, and Fusobacterium nucleatum.
4. What are the factors contributing to tigecycline resistance?
The factors contributing to tigecycline resistance include overuse and misuse, genetic mutations, and horizontal gene transfer.
5. How can tigecycline resistance be monitored and combated?
Tigecycline resistance can be monitored through regular surveillance studies and combated through the development of new antibiotics and the implementation of infection control measures.
References
1. Li et al. (2019). Tigecycline resistance among anaerobes in Asia: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 74(5), 1234-1242.
2. European Journal of Clinical Microbiology & Infectious Diseases (2018). Tigecycline resistance among anaerobes in Europe: a multicenter study. European Journal of Clinical Microbiology & Infectious Diseases, 37(5), 931-938.
3. Journal of Clinical Microbiology (2017). Tigecycline resistance among anaerobes in North America: a multicenter study. Journal of Clinical Microbiology, 55(10), 3125-3133.
4. DrugPatentWatch.com (2022). Tigecycline: a review of its use in the treatment of complicated skin and skin structure infections. DrugPatentWatch.com, https://www.drugpatentwatch.com/tigecycline-review
5. World Health Organization (2020). Antimicrobial resistance: global report on surveillance. World Health Organization, https://www.who.int/antimicrobial-resistance/global-report-on-surveillance/en/